Deutsche Bank (ETR:DBKGn) initiated coverage of Sarepta Therapeutics (NASDAQ:SRPT), assigning a Hold rating to the ...

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands ...

Raymond James resumed coverage of Regenxbio (RGNX) with an Outperform rating and $27 price target The firm expects the launch of Elevidys and ...

The most important therapy in Sarepta Therapeutics' portfolio is Elevidys, which last year earned full FDA approval for use in ambulatory Duchenne muscular dystrophy patients. The medicine also ...

Notably, the 2-year results from the study exhibited significant improvements throughout various measures of Duchenne muscular dystrophy (DMD), reflecting the potential of ELEVIDYS as a treatment.

Some of the market’s biggest winners start off as the smallest players. While trillion-dollar tech giants like the ...

Notably, its commitment to innovation is underscored by substantial R&D investments, which are pivotal in driving forward its gene therapy solutions such as ELEVIDYS for Duchenne muscular ...

Over the last 7 days, the United States market has remained flat, yet it is up 22% over the past year with earnings expected to grow by 15% per annum in the coming years. In this context of steady ...

ELEVIDYS has been granted orphan drug designation for the treatment of anti-GBM disease by both the U.S. Food and Drug Administration and the European Medicines Agency. Q4 also marks the ...